{
  "id": "CD015003.PUB2",
  "draft": "Can colchicine help prevent heart attacks, strokes, and other cardiovascular events in people who have not had any of these problems before? We looked at the evidence to find out. Colchicine is a cheap drug with anti-inflammatory properties that has been used for centuries. It might help prevent heart and blood vessel problems because it can reduce inflammation, a key factor in the development of the disease. However, we still do not know if colchicine can prevent these heart and blood vessel problems for most people. We need more and better research to find out its true benefits and harms.\n\nWhat are the key messages of this review? \n- Colchicine may reduce the risk of death from any cause, but this finding is very uncertain.\n- It may also increase the risk of diarrhoea.\n- We do not know if colchicine can prevent heart attacks, strokes, or other cardiovascular events in people without a history of these problems.\n\nWhat is heart and blood vessel disease? \nHeart and blood vessel disease is a condition where arteries become clogged with fatty substances. This process involves long-term swelling (inflammation) inside the arteries. Because this disease involves inflammation, we wanted to find out if colchicine, an anti-inflammatory drug, could help prevent it.\n\nWhat did the review authors want to find out? \nWe wanted to find out the benefits and harms of using colchicine to prevent cardiovascular events in people who have not had these problems before. We looked at studies that compared colchicine with a placebo, other medicines that affect the immune system, or usual care.\n\nHow did we find the evidence? \nWe searched for studies that compared colchicine to other treatments for preventing cardiovascular events. We summarized the results and rated how confident we are in the evidence.\n\nWhat did we find? \nWe found 15 studies that involved 1721 people. The studies lasted from 4 to 728 weeks. In these studies, researchers compared people taking colchicine by mouth to people taking a placebo, other anti-inflammatory drugs, or having usual care. Most of the studies focused on liver disease rather than the general population. Colchicine may reduce the risk of death from any cause, but we are very uncertain about the results. It may make little to no difference to the risk of non-fatal heart attacks, but we are very uncertain about the results. Colchicine may increase the risk of diarrhoea. For every 100 people taking colchicine, about 10 may experience diarrhoea, compared to about 3 of 100 people not taking colchicine.\n\nWhat are the limitations of this evidence? \nThe evidence is not strong for a few reasons. The main reason is that the people in the studies were not the focus of our review. We wanted to know about preventing heart problems in the general population, but many of the studies we found focused on people with liver disease. This makes it very difficult to know if the results apply to most people. In almost all of the studies, people and their doctors knew which treatment they were getting. This can influence the results, because people's expectations can affect how they report their health. Studies are more reliable when no one knows who is getting the real treatment until the end.\n\nHow up to date is this evidence? \nThe evidence is up to date to May 2023. We need more and better research to find out the true benefits and harms of colchicine for preventing cardiovascular events in people who have not had these problems before.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 606,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 39,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 15.538461538461538,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 10,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 64,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 46,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 19,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "nouns": {
          "value": 149,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "flesch_reading_ease": {
          "value": 65.699105102818,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 7.955808580858086,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 8.06274562071592,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 9.414851485148514,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 11.693932470170095,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 38.80578827113481,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 3.6153846153846154,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 11.774964387392123,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "dale_chall_readability": {
          "value": 5.695311652703733,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words_dc": {
          "value": 189,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words": {
          "value": 83,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "long_words": {
          "value": 141,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        }
      },
      "word_count_status": {
        "word_count": 606,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 606 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 8,
        "P50_count": 3,
        "P75_count": 7,
        "P90_count": 0,
        "P10_count": 0,
        "BEYOND_P90_count": 0,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 44.44444444444444,
        "P50_percentage": 16.666666666666664,
        "P75_percentage": 38.88888888888889,
        "P90_percentage": 0,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 0,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 83.33333333333334,
        "overall_assessment": "HIGHLY CONFORMS TO TYPICAL PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "This is a very well-written draft that is clear, concise, and easy to read. The following suggestions are intended to refine an already strong summary.\n\n1. **Improve the structure by moving a key limitation out of the results section.** The 'What did we find?' section should focus only on the findings. Placing a limitation here disrupts the flow for the reader.\n    *   **Current text:** 'In these studies, researchers compared people taking colchicine by mouth to people taking a placebo, other anti-inflammatory drugs, or having usual care. Most of the studies focused on liver disease rather than the general population. Colchicine may reduce the risk of death from any cause...'\n    *   **Suggestion:** Move the sentence 'Most of the studies focused on liver disease rather than the general population' from the 'What did we find?' section to the 'What are the limitations of this evidence?' section. This keeps the results focused on the outcomes and the limitations focused on the study weaknesses.\n\n2. **Make the definition of heart disease more specific.** The current definition is good, but could be more precise to help readers better understand the condition.\n    *   **Current text:** 'Heart and blood vessel disease is a condition where arteries become clogged with fatty substances.'\n    *   **Suggestion:** Consider a slightly more descriptive definition, such as: 'Heart and blood vessel disease happens when arteries become narrowed by the build-up of fatty deposits called plaque.' This introduces the concept of 'plaque' which is central to the disease.\n\n3. **Ensure consistent terminology for comparator treatments.** The summary uses different phrases to describe the same type of comparator drug, which could be confusing.\n    *   **In 'What did the review authors want to find out?':** '...other medicines that affect the immune system...'\n    *   **In 'What did we find?':** '...other anti-inflammatory drugs...'\n    *   **Suggestion:** Use the simpler, more consistent term in both places. We recommend using 'other anti-inflammatory drugs' throughout the summary.",
      "pls_evaluation_summary": "The linguistic analysis shows the draft highly conforms to typical PLS patterns. All 18 metrics fall within or are better than the median range for Cochrane PLS texts, with 15 (83.3%) in the best quartile. Readability scores like the Flesch-Kincaid Grade (7.96) and words per sentence (15.54) are excellent, indicating the text is very easy to read. The draft effectively uses active voice and personal pronouns, aligning with best practices. The metrics confirm the draft's high quality and readability."
    }
  ]
}